masthead-news.jpg

News & Events

2018 Molecular Pathology in Oncology

Join HTG at the Molecular Pathology in Oncology at stand 7 and learn more about our HTG EdgeSeq PATH Assay. The assay has been designed for retrospective gene expression profiling to complement traditional immunohistochemistry testing by allowing investigators to assess mRNA expression of large numbers of markers when tissue availability is limited.

Biomedical Research Centre | The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research | London, UK | March 15, 2018

Read More

Category: Events
Topics: Molecular Profiling, PATH Assay
Posted on:

HTG Molecular Diagnostics to Participate in Corporate Access Event in San Francisco, January 8 – 10, 2018

TUCSON, Ariz., Dec. 20, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that its senior management team will host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.

Read More

Category: Press Releases
Topics: HTG
Posted on:

HTG Molecular Diagnostics to Announce Third Quarter 2017 Financial Results and Host Conference Call on Tuesday, November 7

TUCSON, Ariz., Oct. 20, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that it will report its financial results for the three and nine months ended September 30, 2017 after the market close on Tuesday, November 7th. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.

Read More

Category: Press Releases
Topics: HTG, Reports
Posted on:

HTG Molecular Diagnostics to Present at the Cantor Fitzgerald Global Healthcare Conference

TUCSON, Ariz., Sept. 25, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced its management will present a corporate overview at the Cantor Fitzgerald Global Healthcare Conference in New York City on Monday, September 25 at 9:45am Eastern Time.

Read More

Category: Press Releases
Topics: HTG, Presentation
Posted on:

HTG Molecular Diagnostics Receives ISO 13485 Certification for Health Canada CMDCAS Requirements

TUCSON, Ariz., Sept. 18, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that is has successfully completed an audit of its Quality Management System for continued certification to ISO 13485. This certification was issued by a registrar accredited under the Canadian Medical Device Conformity Assessment System (CMDCAS), which is required by Health Canada for the company to market in vitro diagnostic (IVD) products in Canada.

Read More

Category: Press Releases
Topics: CMDCAS, HTG, ISO 13485
Posted on:

HTG Molecular Diagnostics Provides Regulatory Update for its HTG EdgeSeq ALKPlus Assay

TUCSON, Ariz., Sept. 11, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that it expects to complete and file the fourth and final module related to the premarket approval application (PMA) submission for its HTG EdgeSeq ALKPlus Assay in the second quarter of 2018. The first three modules of the PMA have already been submitted to the U.S. Food and Drug Administration (FDA) for review.

Read More

Category: Press Releases
Topics: HTG, HTG EdgeSeq ALKPlus Assay EU
Posted on:

Page last updated January 19, 2018